Simcere’s Sublingual Edaravone Nears International Phase III Trial After China Approval

 
• By Dexter Jie Yan
  
stroke.jpg
Sanbexin sublingual significantly improved the ratio of the AIS patients with good functional outcomes by roughly 10 percentage points on day 90.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip